Fundamentally Strong Pharma Stock to Buy Now for an Upside of 20%; Do You Own It?

Synopsis: Citi placed Cipla Ltd on a 90-day Positive Catalyst Watch, retaining a Buy rating with a ₹1,700 target, implying 20% upside. Growth is driven by a strong US respiratory pipeline, regulatory clearances, and recovery in India business. Earnings bottoming, market leadership, and easing cost pressures support improved visibility and valuation.

The shares of the Large-Cap company, which specialises in generic medications, active pharmaceutical ingredients (APIs), and consumer healthcare products, holding global leadership in respiratory care (asthma, COPD), are in focus following the buy target from Citi with an upside potential of 20 percent.

With a market capitalisation of Rs. 1,15,925.80 crores in the day’s trade, the shares of Cipla Ltd rose by 4.1 percent, reaching a high of Rs. 1,461.25 per share compared to its previous closing price of Rs. 1,415.30 per share.

What Happened 

Cipla Ltd, engaged in generic medications, active pharmaceutical ingredients (APIs), and consumer healthcare products, is in focus after Citi placed the stock on a 90-day Positive Catalyst Watch while maintaining its ‘Buy’ rating and target price of Rs 1,700 with an upside potential of 20 percent from the previous close price.

Reason for the Target

Citi expects upcoming approvals like gFlovent and the launch of gVentolin to significantly boost Cipla’s US revenues. These products target large respiratory markets, and successful commercialisation could reverse recent weakness in the US business, making it a key near-term earnings driver and improving overall growth visibility.

The Indore facility’s USFDA re-inspection and potential clearance are crucial triggers. Approval would remove regulatory overhang, restore export potential, and strengthen investor confidence. Alongside the Goa facility approval prospects, these developments could unlock additional revenue streams and support consistent operational performance.

Cipla’s India segment, contributing nearly two-thirds of EBITDA, is showing steady recovery led by its respiratory portfolio. Strong domestic demand, improved execution, and brand strength position the company well versus peers. This stability provides a reliable earnings base while global segments work through volatility.

Cipla’s drug Nintedanib is approaching 50% market share in the US, reflecting strong competitive positioning. High market share in specialised therapies improves pricing power and margins. This leadership strengthens Cipla’s presence in regulated markets and supports sustained revenue growth over the medium term.

Citi believes earnings have bottomed out after the gRevlimid-related decline. With improving business momentum, Cipla trades at reasonable multiples compared to peers. Its India business valuation is still lower than competitors like Mankind Pharma, offering a favourable risk-reward balance for investors.

Easing geopolitical tensions is expected to stabilise raw material supply chains and reduce cost pressures. This improves margin visibility and lowers uncertainty in operations. Combined with business recovery in both the US and India markets, it enhances Cipla’s overall earnings outlook and strengthens the investment case.

The company’s revenue declined by 2.80 percent from Rs. 6,730 crores in March 2025 to Rs. 6,541 crores in March 2026. Meanwhile, Net profit declined from Rs. 1,214 crores to Rs. 543 crores in the same period.

The company shows a reasonably efficient capital structure and moderate profitability. A ROCE of 15.5% indicates decent returns on the capital employed, while an ROE of 11.6% suggests shareholder returns are stable but not very high. The extremely low debt-to-equity ratio of 0.02 highlights a near debt-free balance sheet, which reduces financial risk but may also indicate underutilised leverage for growth.

In valuation terms, the stock P/E of 29.9 is slightly below the industry P/E of 32.3, suggesting it is marginally cheaper than peers on earnings. Combined with a healthy dividend payout of 25.7%, the company appears to offer a balanced mix of moderate growth, low financial risk, and steady shareholder returns, though not necessarily high-growth or high-ROE characteristics.

The company reported revenues of Rs. 6,541 crore in Q4FY26, with a strong concentration in domestic operations. One India remained the largest contributor at 46% of total revenue, followed by North America at 22%, showing a significant international presence as well.

The remaining revenue mix came from One Africa at 19% and Emerging Markets & Europe at 12%, while API and others contributed a marginal 1%. Overall, the breakdown highlights a diversified geographic footprint, though heavily weighted toward the Indian market.

As of 31st March 2026, the portfolio consists of 181 approved ANDAs & NDAs, along with 49 tentatively approved applications. This reflects a strong base of already cleared regulatory filings supporting current and near-term product commercialisation.

In addition, there are 55 ANDAs & NDAs under approval, bringing the total pipeline to 285 applications. This indicates a healthy ongoing submission and review pipeline, supporting future growth potential.

Cipla Ltd is one of India’s leading pharmaceutical companies, founded in 1935 and headquartered in Mumbai. It is known for developing and manufacturing affordable medicines across a wide range of therapeutic areas, including respiratory, cardiovascular, anti-infectives, and HIV/AIDS treatments. Cipla has a strong global presence, supplying medicines to many countries and focusing on improving access to healthcare, especially in developing regions.

The company operates a large network of manufacturing facilities and research centres, with an emphasis on innovation and quality. Cipla is also recognised for its role in making life-saving drugs more affordable, particularly in the treatment of chronic and critical illnesses.

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post Fundamentally Strong Pharma Stock to Buy Now for an Upside of 20%; Do You Own It? appeared first on Trade Brains.